Initiation of ReLive, phase III clinical trial with Livatag® in primary liver cancer (PDF - 280 Ko)
BioAlliance Pharma announces two new key steps in the development of its AMEP® biotherapy (PDF - 289 Ko)
Combined Ordinary and Extraordinary General Meeting on May 31, 2012: Procedures for obtaining preparatory documents (PDF - 65 Ko)
Publication of the 2011 Registration Document (PDF - 59 Ko)
Full-year financial results for 2011 - Q1 2012 Consolidated turnover: A growth strategy focused on orphan oncology products, Promising products in advanced development, Reinforced cash reserves at €28.7 million as of December 31, 2011 (PDF - 185 Ko)
BioAlliance Pharma announces:New achievements in clonidine Lauriad™ clinical development, Second product of its orphan oncology portfolio (PDF - 126 Ko)
« Oncology: key issues for the future » - Success of the first BioAlliance Pharma’s symposium (PDF - 196 Ko)
To gain a better understanding of the company, its product portfolio and its management team, BioAlliance Pharma organizes a symposium "Oncology: key issues for the future" (PDF - 205 Ko)
